Sasaki Akinori, Harano Kenichi, Kogawa Takahiro, Matsubara Nobuaki, Naito Yoichi, Hosono Ako, Mukai Hirofumi, Yoshino Takayuki, Mukohara Toru
Department of Breast and Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Case Rep Oncol Med. 2020 Jun 16;2020:7231358. doi: 10.1155/2020/7231358. eCollection 2020.
Intestinal perforation is a rare adverse event of antineoplastic therapy. However, once it occurs, it is potentially fatal. This report describes a case of intestinal perforation caused by bevacizumab in a patient with ovarian cancer who concurrently developed neutropenic enterocolitis. A 66-year-old woman diagnosed with metastatic ovarian cancer received combination chemotherapy with carboplatin, gemcitabine, and bevacizumab. On day 14, she developed grade 4 pancytopenia and febrile neutropenia, which resulted in neutropenic enterocolitis and intestinal perforation. Emergency surgery was performed, and an intestinal perforation found in the ascending colon was closed. Postoperatively, she developed an intra-abdominal abscess requiring peritoneal drainage. She was discharged from the hospital on recovery.
肠穿孔是抗肿瘤治疗中一种罕见的不良事件。然而，一旦发生，它可能是致命的。本报告描述了1例卵巢癌患者在接受贝伐单抗治疗时发生肠穿孔并同时并发中性粒细胞减少性小肠结肠炎的病例。一名66岁被诊断为转移性卵巢癌的女性接受了卡铂、吉西他滨和贝伐单抗的联合化疗。在第14天，她出现了4级全血细胞减少和发热性中性粒细胞减少，进而导致中性粒细胞减少性小肠结肠炎和肠穿孔。患者接受了急诊手术，术中发现升结肠的肠穿孔并进行了修补。术后，她出现了腹腔脓肿，需要进行腹腔引流。康复后她出院了。
